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ABSTRACT Patients with acute exacerbated chronic obstructive pulmonary disease (AECOPD) and
concurrent depression suffer significant psychological stress and decreased quality of life. The aim of this
study was to collate data, guidelines and recommendations from publications on the screening and
management of depressive mood disorders in patients hospitalised with AECOPD.
We systematically searched four databases for publications reporting screening or management of
depression in patients hospitalised for AECOPD. The identification of articles was based on the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement.
Out of 1494 original articles screened, 35 met all inclusion criteria. These report a prevalence of
depression in AECOPD ranging between 9.5% and 85.6%. Some studies report high postadmission
mortality rates for depressive AECOPD patients, and higher readmission rates in depressive versus
nondepressive AECOPD patients. Importantly, none of the 35 publications included suggestions on the
screening and management of depression in AECOPD.
Depression and AECOPD frequently co-occur, and this worsens outcomes. Yet we did not find
recommendations on management, and few interventional studies. Patients hospitalised with AECOPD
should be systematically screened for depression and treatment recommendations should be developed for
these patients. Randomised studies on how to screen and treat depression in hospitalised AECOPD are
necessary.
Copyright ©ERS 2017. ERR articles are open access and distributed under the terms of the Creative Commons
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Introduction
Chronic obstructive pulmonary disease (COPD) is a progressively incapacitating multisystem disease that
worsens the patient’s physical and psychosocial functioning [1, 2]. Thus, functional impairment in COPD
is known to lead to psychiatric comorbidity [3–5], e.g. elevated incidence of depression [5]. Contrariwise,
depression adversely affects functional ability and quality of life in COPD. Furthermore, depression is a
risk factor for readmission to hospital for acute exacerbation of COPD (AECOPD) [6–8].
The pathophysiological mechanisms underpinning the relationship between AECOPD and depression are
not well understood (for a detailed review, see [9]). For example, physical limitations, hypoxia, smoking
and “overspilling” lung inflammation appear to elevate levels of personal distress and depressive mood [8],
but the degree of personal distress does not depend on the severity of lung disease [10]. Systemic
short-term glucocorticoid therapy for AECOPD does not trigger depressive mood symptoms [11], but
inflammation and long-term administration of glucocorticoids contribute to depressive mood disorders
[12–14].
Given the harmful interactions between COPD and depression, it is noteworthy that depression is widely
underdiagnosed and undertreated in patients with COPD [8], even if these harmful interactions are not
well understood. Nevertheless, the Swiss guideline on management of COPD lacks attention to the
patient’s state of mind and depressed mood [15]. It focuses solely on the treatment of the underlying
respiratory disease and symptoms, even though depression is a common comorbidity. Other important
guidelines provided by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) and the
National Institute for Health and Care Excellence acknowledge the high prevalence of depression in COPD
patients, but they lack advice on screening or intervention for depression [16, 17].
This is the first systematic review assessing the prevalence of depressive mood disorders in patients
primarily hospitalised due to AECOPD and collating recommendations for the screening and management
of this comorbidity.
Methods
Search strategy
We conducted a comprehensive search of all publications until October 6, 2015, using the databases
MEDLINE, Embase and the Cochrane Library. Previous research in other fields of medicine has shown
that combining the databases of MEDLINE, Embase and Cochrane can yield a recall rate as high as 97%
[18]. Hence, missing relevant publications is very unlikely. Nevertheless, we included PsycINFO to identify
publications with a more psychotherapeutic focus. The database searches focused on English language
publications, irrespective of country of origin, relating to patients hospitalised for AECOPD, depression in
AECOPD and interventions for management of depression in AECOPD.
The search terms are summarised in table 1. These terms were combined using the Boolean operator
“and” to search through titles, abstracts and key words. After selecting articles, we merged the results from
the four databases and eliminated any duplicates, using EndNote X7 (Thomson Reuters, Zug,
Switzerland).
Selection criteria
The review included all articles fulfilling the inclusion criteria, i.e. study related to a hospitalised
population of AECOPD, screening and/or management for depression and availability as a full-text article.
Articles not written in English and articles without abstracts were excluded. The selection criteria were
developed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement [19].
TABLE 1 Search terms
“chronic obstructive lung disease” or (“pulmonary” or “lung” or “airway” or “airflow” or
“bronchopulmonary” or “respiratory” and (“disease” or “disorder”) and “chronic” and (“obstructive” or
“obstruction”))
AND
“depression” or “depressive” and (“disorder” or “disease” or “patient” or “patients” or “syndrome” or
“symptom” or “episode” or “illness”) or “depressive disorder” or “depression”
AND
“hospitalisation” or “rehospitalisation” or “exacerb*” or “aggravat*” or “flare” or “admission” or
“readmission” or “readmitted”
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Study selection
LL initially searched the electronic databases. Subsequently, a screening of the abstracts based on the
inclusion criteria was conducted. The inclusion criteria are summarised in table 2. If screening of abstracts
was inconclusive, the full-text article was screened for the criteria. Disagreements were resolved by
consensus between the authors LL, MR, DF and AN.
Data extraction
The data were extracted by one author (LL) from each publication according to the following categories:
study type, characteristics of population, number of patients, evaluation of depression, outcome of
readmission rate, outcome of mortality, follow-up, intervention and results. Another author (AN) checked
the extracted data. Figure 1 shows a flow chart of the process of study selection.
Quality assessment
For quality assessment, a randomly selected 10% of the initial publication sample was reviewed by the
coauthors AN, MR and DF. The results were compared and discrepancies discussed. Disagreements were
resolved by consensus between the authors LL, MR and DF.
Results
Identification of publications
The initial search generated a total of 1793 publications from the four databases. There were 1494
publications after removal of all duplicates. 80 of these publications were referred to full text review
because screening of the abstracts indicated eligibility for our study. After reviewing the full texts, 35
publications met all inclusion criteria [8, 20–53]. Seven of these were reviews, 11 conference abstracts and
17 were full-text studies. No further publications were found by checking the reference lists of these
articles.
The 35 publications provide data about depression within a population of hospitalised patients due to
AECOPD. In nine of them, readmissions between 1 month and 1 year were reported. Mortality was
assessed in six studies covering a range of ⩽2 years. Table 3 shows a summary of all 35 studies that met
the inclusion criteria.
Prevalence of concurrent depression in hospitalised AECOPD patients
The 35 final publications described depression and AECOPD as a frequent comorbidity in hospitalised
patients. The prevalence of depression was high or very high according to all publications, ranging from
9.5% to 85.6%. However, the methods used for the assessment of depression were different, since the tools
to screen for depression, severity criteria and timeframe in which depression was evaluated during
exacerbation phase varied among the publications included.
Therapeutic guidelines for concurrent depression and AECOPD
None of the 35 publications included suggestions, guidance or guidelines for treatment of depression in
patients with AECOPD. However, three studies investigated interventions applied in those patients (see
later). Of the seven reviews, none gave advice regarding therapy adjustments in depressive AECOPD
patients. All seven reviews focused on the impact and relationship of depression on COPD, with three
targeting the effect on exacerbation rates from depression in COPD patients. Depression is found to be
uniformly high in COPD patients, correlating with a worse outcome regarding survival, hospitalisation
rates and symptoms. However, none gave specific recommendations regarding operationally usable
potential methods of screening or treatment for patients hospitalised for a primary diagnosis of AECOPD
[8, 29, 38, 39, 42, 44, 46].
Table 3 provides a summary of the depression and assessment methods used in the articles reviewed.
TABLE 2 Inclusion criteria
Studies including participants primarily hospitalised due to an
acute exacerbation of chronic obstructive pulmonary
disease
AND a screening for depressive mood
disorders in those patients
AND/OR a guided management of
depressions in those patients
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Readmission rate and mortality
Readmission after hospitalisation due to AECOPD was investigated in seven of the publications included
[20, 22, 26, 31, 34, 35, 43, 48]. 30-day and 1-year readmission rates were 10.4–24.1% and 29.0–84.6%,
respectively. Four out of these seven studies reported a significantly higher readmission rate in depressive
compared with nondepressive AECOPD patients (20–84.6% versus 16–28.1%) [26, 31, 43, 48].
Mortality in depressive patients hospitalised for AECOPD was investigated in six publications [21, 22, 27,
40, 43, 47]. 30-day and 1-year mortality rates were 5.3–7.2% and 9.8–25.3%, respectively. Five of these
studies stated a significantly higher mortality in depressive patients during the follow-up period between
30 days and 2 years compared to nondepressive patients [21, 22, 26, 40, 43]. One study failed to find a
higher mortality in depressive AECOPD patients. However, while other studies focused on post-discharge
mortality, this study investigated in-hospital mortality [47].
Treatment interventions
Three publications considered therapeutic interventions. An adjusted regime of physical therapy [51, 52]
and a programme of counselling and education of the inpatient and primary health care team were
investigated [34].
The physical therapeutic interventions were based on a combination of deep breathing and limb exercises
daily for 30–45 min in one study and a controlled breathing programme twice daily for 30 min in the
second study. Both showed a significant effect on the outcome of depression. Patients showed
improvements in symptoms such as dyspnoea, anxiety and mobility, as well as depression [51, 52].
In the third study, an intervention bundle including counselling and reporting of depression to the
healthcare team was investigated in patients hospitalised with AECOPD. However, the intervention did not
significantly affect depression [34].
Discussion
The reviewed publications uniformly confirm that depression is a common, relevant and problematic
comorbidity in patients with COPD [8]. In addition, depression is known to be associated with higher
rates of readmission and increased mortality after hospitalisations due to AECOPD [44, 46]. However,
these studies are based on heterogeneous patient populations due to differences in applied patient selection
criteria. For instance, the prevalence of depression has been applied in some studies as a baseline value for
depression, while others use it as an exclusion criterion [45, 47, 48, 53]. Presumably, this is the main
reason for the differences in the prevalence of depression among the included studies, which ranges from
slightly below 10% to almost 90%. These prevalences are considerably higher than in the general
population and similar to those in diseases such as cancer [54] and persons infected with HIV [55].
Furthermore, different measures of depressive symptoms and depression and different cut-off thresholds
have been applied. The tool used most commonly was the Hospital Anxiety and Depression Scale
FIGURE 1 Identification of eligible
studies.
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TABLE 3 Studies that met the inclusion criteria and were reviewed
First author (year)
[ref.]
Study type and characteristics
of study population
Patients n Evaluation of depression Readmissions Mortality Follow-up
ABRAMS (2011) [22] Retrospective study of mostly
male (97%) veterans from
2006 to 2008 hospitalised for
AECOPD
26591 Prevalent in 11.6% (n=3077) In a 30-day period 10.4%
(n=319) with prevalent
depression versus 11.6%
(n=2723) with no depression
In a 30-day period 5.3% (n=163)
with prevalent depression
versus 3.8% (n=881) with no
depression
30 days
REGVAT (2011) [45] Prospective study of patients
hospitalised for AECOPD
Patients with prevalent
psychiatric disorders,
including depression, were
excluded
50 Evaluation of depression
through PRIME-MD
questionnaire on day of
discharge; 42% (n=21)
indicated depression
n/a n/a n/a
PUMAR (2014) [8] Review n/a n/a n/a n/a n/a
SINGH (2016) [48] Retrospective cohorts of
patients hospitalised for
AECOPD in 2001–2011 and
aged >66 years
80088 patients with
a total of 135498
hospitalisations
Prevalent in 14.24% of
hospitalisations (n=19293)
In a 30-day period 24.15%
(n=4659) with prevalent
depression versus 16.91 (n=19
645) with no depression
n/a 30 days
NG (2014) [40] Prospective cohort study of
patients hospitalised for
AECOPD
Conference abstract
376 HADS score ⩾8 in 44.4%
(n=167)
n/a In a 1-year period a hazard
ratio of 1.93 (95% CI 1.04–3.58)
for mortality was associated
with baseline depression
1 year
CAVAILLÈS (2013) [29] Review n/a n/a n/a n/a n/a
IRWIN (2015) [33] Prospective study of patients
hospitalised for AECOPD
Patients with prevalent
psychiatric disorders, including
depression, were excluded
85 PROMIS measurement of
depression was positive in
44% (n=35)
n/a n/a n/a
SALTE (2015) [46] Review n/a n/a n/a n/a n/a
AIMONINO (2007) [23] Prospective study of patients
aged ⩾75 years hospitalised
for AECOPD from April 2004 to
April 2005
16 Geriatric depression scale
Mean±SD depression score
of 12.8±5.4 at baseline and
12.68±n/a at discharge
n/a n/a n/a
YILDIRIM (2013) [53] Prospective study of patients
hospitalised for AECOPD
Patients with prevalent
psychiatric disorders, including
depression, were excluded
135 HADS (Turkish translated
version) score ⩾8 in 85.6%
(n=116)
n/a n/a n/a
VALENZA (2014) [52] Prospective randomised cohort
study of male patients
hospitalised for AECOPD
Intervention with a controlled
breathing programme
46 Baseline mean±SD HADS
score of 9.62±2.1 in the
intervention group and
8.85±4 in the control group
n/a n/a n/a
Continued
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TABLE 3 Continued
First author (year)
[ref.]
Study type and characteristics
of study population
Patients n Evaluation of depression Readmissions Mortality Follow-up
AL AQQAD (2014) [25] Prospective study from
January 2016 to June 2016 in
Malaysia
Patients hospitalised for
AECOPD and aged >60 years
Conference abstract
37 45.9% showed symptoms of
depression (no further
clarification of test
method); 5.4% categorised
as severe and 40.5% as
mild to moderate
n/a n/a n/a
POOLER (2014) [44] Review n/a n/a n/a n/a n/a
LAURIN (2012) [39] Review n/a n/a n/a n/a n/a
PAPAIOANNOU
(2013) [43]
Prospective study of patients
hospitalised for AECOPD
between March 2009 and June
2010 without prevalent
depression
230 Beck depression inventory
(Greek translation) score
⩾19 in 39.57% (n=91) on the
first day of hospitalisation
84.6% (n=77) with 1.96±1.41
readmissions for depressive
patients versus 28.1% (n=39)
with 0.41±0.86 readmissions for
nondepressive patients within
1 year
25.3% (n=23) for depressive
patients versus 3.6% (n=5) for
nondepressive patients within
1 year
1 year
LAURIN (2011) [38] Review n/a n/a n/a n/a n/a
OZYEMISCI-TASKIRAN
(2015) [41]
Retrospective study of patients
hospitalised for AECOPD
Two hospitalised control
groups: one with stable COPD
and one without COPD
133 (AECOPD); 34
(stable COPD); 34
(without COPD)
HADS (Turkish translation)
score ⩾8 in 39.1% (n=52);
mean score 5 (Q1=2; Q3=11)
for AECOPD
HADS score ⩾8 in 14.7%
(n=5); mean score 4
(Q1=0.25; Q3=6) for stable
COPD
HADS score ⩾8 in 29.4%
(n=10); mean score 4.5
(Q1=1; Q3=8.25) for
non-COPD
n/a n/a n/a
ALMAGRO (2002) [27] Prospective study of patients
(mostly male, 96%)
hospitalised for AECOPD
between October 1996 and
May 1997
135 YDS was applied, but no
direct data provided
n/a Patients with YDS score ⩾11
had a 3.11-fold higher
mortality than patients with a
YDS score ⩽5 within 2 years
2 years
PANAGIOTI (2014) [42] Review n/a n/a n/a n/a n/a
SMALL (1992) [49] Prospective study of patients
hospitalised for AECOPD
26 Profile of Mood States was
applied
Mean±SD score for
depression of 13.35±12.38
and median score 11.5
No cut-off value for
depression was provided by
the test
n/a n/a n/a
Continued
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TABLE 3 Continued
First author (year)
[ref.]
Study type and characteristics
of study population
Patients n Evaluation of depression Readmissions Mortality Follow-up
KOENIG (2006) [36] Prospective cohort study of
patients aged >50 years
hospitalised for AECOPD
between November 1999 and
December 2003
No data provided on
overall rates of
depression of
screened patients
Patients were identified as
depressive using the
Structured Clinical
Interview for Diagnostic and
Statistical Manual of Mental
Disorders (4th edition)
410 patients were classified
with minor deperession and
301 with major depression
using the Hamilton
Depression Rating Scale
n/a n/a At an average follow-up of
11.4 weeks minor
depressions showed
remission of 66.6% (n=273)
and at an average follow-up
of 21.3 weeks for major
depressions 49.2% (n=148)
showed remission
JENNINGS (2015) [34] Randomised trial of patients
admitted with AECOPD
between February 2010 and
April 2013 and with smoking
history ⩾20 pack-years
172 in total;
(intervention group
n=93; control group
n=79)
HADS was applied in the
intervention group, but no
baseline values are
provided
No significant association
between depression score per
1-unit increase and
Readmission for 30-day
follow-up (HR 1.11, 95% CI
0.96–1.27; p=0.157) and 90-day
follow-up (HR 1.057, 95% CI
0.95–1.17; p=0.300)
n/a 30 days and 90 days
SILVER (2010) [47] Cross-sectional study of
patients hospitalised for
AECOPD between January
2007 and December 2007
Conference abstract
69841 Prevalent diagnosis of
anxiety/depression present
in 27.3%
No seperated data provided
n/a Odds ratio for in-hospital
mortality 0.93 (95% CI 0.81–
1.06)
n/a
TORRES-SÁNCHEZ (2016)
[51]
Randomised, single-blind
clinical trial of obese patients
hospitalised for AECOPD
49 (intervention
group n=24; control
group n=25)
HADS mean±SD score at
baseline: intervention group
6.0±2.86; control group 4.90
±2.84
p=0.218
n/a n/a Follow-up evaluation at
discharge
KIM (2010) [35] Retrospective study of 77
patients hospitalised for
AECOPD between January
2005 and May 2008
77 Patients with prevalent
diagnosis of anxiety/
depression and patients
taking psychotropic
medication were considered
to have anxiety/depression
No seperated data of
anxiety/depression were
provided
11.9% (n=9) of patients had
anxiety/depression
Frequent exacerbators (n=35)
(>1 hospitalisation within
1 year) showed 20% (n=7)
anxiety/depression versus 4.8%
(n=2) of single exacerbators
(n=42)
n/a n/a
Continued
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TABLE 3 Continued
First author (year)
[ref.]
Study type and characteristics
of study population
Patients n Evaluation of depression Readmissions Mortality Follow-up
ALMAGRO (2006) [26] Prospective study of patients
hospitalised for AECOPD
between October 1996 and
May 1997
129 YDS was applied, but no
general baseline data are
provided
Score ⩾5 is considered as
cut-off for depression
YDS mean±SD score of 5±3.4 for
patients who were readmitted
within 1 year versus 3.7±3.1 for
patients without readmission
within 1 year
58.1% were readmitted within
1 year
n/a 1 year
GUDMUNDSSON (2005)
[31]
Prospective study of patients
hospitalised for AECOPD
during 2000–2001
406 HADS mean±SD score 5.5
±3.6
HADS score ⩾8 in 28.7%
60.59% (n=246) readmitted
within 1 year versus 39.41%
(n=160) without readmission in
1 year
No significant difference
between groups in mean HADS
score (5.4±3.4 versus 5.6±3.8;
p=0.63) and depression level
(26.5% versus 30.2%; p=0.44)
n/a 1 year
STRUIK (2013) [50] Cross-sectional study of
patients hospitalised for
AECOPD between 2008 and
October 2011 with GOLD III or
IV disease and after 48 h of
receiving invasive or
noninvasive ventilation
170 HADS mean±SD score 7.8±SD n/a n/a n/a
AIMONINO RICAUDA
(2008) [24]
Prospective study of patients
aged ⩾75 years hospitalised
for AECOPD between April
2004 and April 2005
The authors published a
similar article including partly
the same population in 2007
[27]
52 Geriatric Depression Scale
Mean±SD depression score
17.2±6.8 at baseline and a
mean±SD change of +0.7
±3.2% at 6-month follow-up
n/a n/a n/a
ABRAMS (2010) [21] Retrospective cohort study of
veterans hospitalised for
AECOPD between October
2016 and September 2007
Conference abstract
23306 Pre-existing depression
was assessed from data
collected 1 year prior to
admission
9.5% (n=2.216) had
pre-existing depression
n/a Unadjusted 30-day mortality
was higher in patients with
depression (7.2% versus 4.6%)
Unadjusted 365-day mortality
was similar in patients with
depression (9.8% versus 9.1%)
Adjusted odds ratio of 30-day
mortality with depression
relative to those without 1.52
(95% CI 1.24–1.86); adjusted
odds ratio of 365-day mortality
with depression relative to
those without 1.2 (95% CI
1.04–1.39)
n/a
Continued
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TABLE 3 Continued
First author (year)
[ref.]
Study type and characteristics
of study population
Patients n Evaluation of depression Readmissions Mortality Follow-up
BURR (2010) [28] Retrospective study of patients
hospitalised for AECOPD in
2008
Two groups where defined:
frequent exacerbators (>1
AECOPD event in 2008) and
single AECOPD event in 2008
Conference abstract
Frequent
exacerbators n=85;
nonfrequent
exacerbators n=89
Depression prevalent in
42% of frequent
exacerbators
No data provided for
nonfrequent exacerbators
n/a n/a n/a
AARON (2013) [20] Retrospective study of patients
hospitalised for AECOPD in
2010
Conference abstract
388 n/a The study does not distinguish
between depression and anxiety
29% of patients with prevalent
depression/anxiety where
readmitted within 1 year versus
16% of patients without
depression/anxiety
n/a n/a
LAÇIN (2011) [37] Study of patients hospitalised
for AECOPD between January
2010 and February 2011
Conference abstract
114 HADS score ⩾8 in 53%
(n=60), mean±SD HADS
score 7.0±5.7
n/a n/a n/a
HASAN (2011) [32] Study of patients hospitalised
for AECOPD
Patients with pneumonia,
heart failure, on long-term
oral corticosteroids, any
significant comorbid condition
or active malignancy were
excluded
Conference abstract
120 HADS was applied within
2 days of hospitalisation
HADS scores ⩾11 in 28%
(n=34)
n/a n/a n/a
FRANZEN (2014) [30] Study of patients hospitalised
between January 2012 and
December 2012 in three public
hospitals in Zurich canton for
AECOPD
Conference abstract
94 Diagnosis of depression
was present in 17%
n/a n/a n/a
AECOPD: acute exacerbation of chronic obstructive pulmonary disease; PRIME-MD: Primary Care Evaluation of Mental Disorders; HADS: Hospital Anxiety and Depression Scale; PROMIS:
Patient-reported Outcomes Measurement Information System; YDS: Yesavage Depression Scale; GOLD: Global Initiative for Chronic Obstructive Lung Disease.
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(HADS), a questionnaire containing 14 questions, of which seven are targeted at symptoms of anxiety and
seven at symptoms of depression. Each question is scored from 0 to 3, which gives a minimum/maximum
scale of 0–21 individually for depression and anxiety. Somatic symptoms are not assessed to detect
depression more reliably in patients with physical health problems [56]. Yet in the studies using the
HADS, the reported prevalence of depression varied extensively, ranging from 25% to 85% [20–28, 30–37,
40, 41, 43, 45, 47–53]. It is possible that there are language-related differences in the psychometric
properties of the HADS in different countries, despite a good internal consistency (i.e. Cronbach’s α).
Furthermore, versions of the HADS in some languages favour three- or four-factor models rather than the
two-factor model applied to the HADS [57].
The identified studies indicate a higher readmission rate in depressive patients hospitalised for AECOPD
and higher mortality after discharge. Thus, we tentatively conclude that in AECOPD depression strongly
relates to poorer outcomes. Hence, further studies with larger patient samples are needed to more precisely
investigate the association between AECOPD and depression [2]. Results from the present review suggest
that there is potential and substantial benefit to be gained by early screening for and treatment of
depression in patients hospitalised for AECOPD. In addition, it would be of interest for further studies to
analyse whether the rate of depression in these patients is associated with other frequent somatic
comorbidities in COPD (i.e. right heart failure, diabetes, kidney insufficiency and amyotrophy), as this has
not been addressed in the identified literature.
Furthermore, we aimed to summarise recommendations given in the studies investigated in this article for
the screening and management of depressive mood disorders in patients hospitalised due to AECOPD.
Disappointingly, none of these publications provided any specific suggestions or recommendations.
However, the wide range of the reported prevalence of depression among these patients suggests that
further development and validation of screening methods for depression in patients hospitalised for
AECOPD is needed. This would help to ensure the reliability of measures like the HADS or the two- and
nine-question patient health questionnaires (PHQ-2 and PHQ-9) specifically for AECOPD. For the
purpose of enhancing cross-national standards of screening, this might also include consideration of
potential differences in response style of respondents (and specifically patients) across different countries
(and languages) in self-report instruments [58].
We found little information on the management of depression in AECOPD patients in the publications
included in this study. None of the publications address the use of psychotherapy or the initiation of
antidepressive medication in patients hospitalised for AECOPD. Two interventional studies indicated an
improvement of depressive symptoms in patients treated with an adjusted physical therapy regime during
the acute phase of AECOPD [51, 52], although it should be noted that these findings were based on very
small patient samples in both studies.
The impact of reporting the presence of depressive symptoms to primary care and acute care medical
teams was examined in one study, but reporting led to no significant improvement in readmission rates
[34]. Importantly, it was not assessed whether this information actually resulted in adjustment of the
therapy.
KOENIG [36] found that depressive patients hospitalised for AECOPD and treated with antidepressants had
more severe and prolonged depressions. A possible explanation for this finding might be that medication
was only given to patients with more severe depression. It is notable that only 46.2% of patients identified
as depressive received antidepressant medication, and only 14.6% received any form of psychotherapy.
Intervention studies on early onset of psychiatric treatment (antidepressive medication and/or
psychotherapy) are urgently needed, especially regarding our findings on the outcome of hospitalised
AECOPD patients with depression.
Although there is a lack of data on the effects of therapy adjustment, we recommend basic screening for
depression (e.g. HADS or PHQ-9) in all patients hospitalised for AECOPD. As guidelines for HIV patients
recommend screening for depression of these at-risk patients [55] and the US Preventive Services Task
Force recommends screening of all patients [59], it is indispensable to screen for depression in this
high-risk patient population.
In summary, the present review demonstrates that depression in patients hospitalised for AECOPD is
common, irrespective of the method used to assess depression and the selection criteria applied for
recruiting patients for the studies. The present review shows also that extremely little research has been
conducted on how to best manage these patients. The outlook of the studies included in this review is
consistent with the idea that more systematic application of validated interventions for AECOPD patients
with depression should be developed. In fact, prospective and randomised studies to identify optimal
screening for depression and to assess potential improvements of outcomes with different treatment
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modalities of depression are urgently required in this group of patients. Thus, prospective randomised
interventional clinical studies on the effect of therapy adjustments such as early psychotherapeutic
interventions, antidepressant medication and intensified physical therapy in depressive patients
hospitalised with a primary diagnosis of AECOPD are needed.
Conclusion
The co-occurrence of AECOPD and depression seems to result in increased readmission rates and
long-term mortality. However, data on screening and management of depressive patients with AECOPD
are scarce and heterogeneous. Further studies are urgently needed to adapt screening tools for depression
in AECOPD and to investigate potential therapeutic interventions and their effect on the outcome.
References
1 de Godoy DV, de Godoy RF. A randomized controlled trial of the effect of psychotherapy on anxiety and
depression in chronic obstructive pulmonary disease. Arch Phys Med Rehabil 2003; 84: 1154–1157.
2 Hynninen KM, Breitve MH, Wiborg AB, et al. Psychological characteristics of patients with chronic obstructive
pulmonary disease: a review. J Psychosom Res 2005; 59: 429–443.
3 Anderson KL. The effect of chronic obstructive pulmonary disease on quality of life. Res Nurs Health 1995; 18:
547–556.
4 Kaptein AA, Brand PL, Dekker FW, et al. Quality-of-life in a long-term multicentre trial in chronic nonspecific
lung disease: assessment at baseline. The Dutch CNSLD Study Group. Eur Respir J 1993; 6: 1479–1484.
5 Kim HF, Kunik ME, Molinari VA, et al. Functional impairment in COPD patients: the impact of anxiety and
depression. Psychosomatics 2000; 41: 465–471.
6 Atlantis E, Fahey P, Cochrane B, et al. Bidirectional associations between clinically relevant depression or anxiety
and COPD: a systematic review and meta-analysis. Chest 2013; 144: 766–777.
7 Ng TP, Niti M, Tan WC, et al. Depressive symptoms and chronic obstructive pulmonary disease: effect on
mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007;
167: 60–67.
8 Pumar MI, Gray CR, Walsh JR, et al. Anxiety and depression – important psychological comorbidities of COPD. J
Thorac Dis 2014; 6: 1615–1631.
9 Decramer M, Rennard S, Troosters T, et al. COPD as a lung disease with systemic consequences – clinical impact,
mechanisms, and potential for early intervention. COPD 2008; 5: 235–256.
10 Wagena EJ, Arrindell WA, Wouters EF, et al. Are patients with COPD psychologically distressed? Eur Respir J
2005; 26: 242–248.
11 Horowitz MA, Zunszain PA, Anacker C, et al. Glucocorticoids and inflammation: a double-headed sword in
depression? How do neuroendocrine and inflammatory pathways interact during stress to contribute to the
pathogenesis of depression? Mod Trends Pharmacopsychiatry 2013; 28: 127–143.
12 Brown ES, Vera E, Frol AB, et al. Effects of chronic prednisone therapy on mood and memory. J Affect Disord
2007; 99: 279–283.
13 Brown ES, Suppes T, Khan DA, et al. Mood changes during prednisone bursts in outpatients with asthma. J Clin
Psychopharmacol 2002; 22: 55–61.
14 Naber D, Sand P, Heigl B. Psychopathological and neuropsychological effects of 8-days’ corticosteroid treatment.
A prospective study. Psychoneuroendocrinology 1996; 21: 25–31.
15 Russi EW, Karrer W, Brutsche M, et al. Diagnosis and management of chronic obstructive pulmonary disease: the
Swiss guidelines. Official guidelines of the Swiss Respiratory Society. Respiration 2013; 85: 160–174.
16 Global Initiative for Chronic Obstructive Lung Disease. GOLD 2017 Global Strategy for the Diagnosis,
Management and Prevention of Chronic Obstructive Pulmonary Disease. http://goldcopd.org/
gold-2017-global-strategy-diagnosis-management-prevention-copd/ Date last accessed: December 14, 2016.
17 National Institute for Health and Care Excellence. Chronic Obstructive Pulmonary Disease in Over 16s: Diagnosis
and Management. www.nice.org.uk/guidance/cg101 Date last accessed: December 14, 2016. Date last updated:
June 2010.
18 Harris JD, Quatman CE, Manring MM, et al. How to write a systematic review. Am J Sports Med 2014; 42:
2761–2768.
19 Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and
meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol
2009; 62: e1–e34.
20 Aaron CP, Yip NH, Brinson MD, et al. Chronic obstructive pulmonary disease hospitalizations in 2010: factors
associated with readmission. Am J Respir Crit Care Med 2013; 187: A4384.
21 Abrams T, Rosenthal G, Sarrazin M. Assessing the impact of anxiety and depression on chronic obstructive lung
disease mortality. J Gen Intern Med 2010; 25: S225.
22 Abrams TE, Vaughan-Sarrazin M, Vander Weg MW. Acute exacerbations of chronic obstructive pulmonary
disease and the effect of existing psychiatric comorbidity on subsequent mortality. Psychosomatics 2011; 52:
441–449.
23 Aimonino N, Tibaldi V, Barale S, et al. Depressive symptoms and quality of life in elderly patients with
exacerbation of chronic obstructive pulmonary disease or cardiac heart failure: preliminary data of a randomized
controlled trial. Arch Gerontol Geriatr 2007; 44: Suppl. 1, 7–12.
24 Aimonino Ricauda N, Tibaldi V, Leff B, et al. Substitutive “hospital at home” versus inpatient care for elderly
patients with exacerbations of chronic obstructive pulmonary disease: a prospective randomized, controlled trial.
J Am Geriatr Soc 2008; 56: 493–500.
25 Al Aqqad S, Ali I, Kassim R, et al. Evaluation of the characteristics, anxiety, and depression among older patients
hospitalized for acute exacerbations of chronic obstructive pulmonary disease. Chest 2014; 145: 393A.
https://doi.org/10.1183/16000617.0026-2017 11
COPD | L. LECHELER ET AL.
26 Almagro P, Barreiro B, Ochoa de Echaguen A, et al. Risk factors for hospital readmission in patients with chronic
obstructive pulmonary disease. Respiration 2006; 73: 311–317.
27 Almagro P, Calbo E, Ochoa de Echagüen, et al. Mortality after hospitalization for COPD. Chest 2002; 121:
1441–1448.
28 Burr L, Tay G, Tang T, et al. Characteristics of the frequent COPD exacerbators at the Gold Coast hospital.
Respirology 2010; 15: A60.
29 Cavaillès A, Brinchault-Rabin G, Dixmier A, et al. Comorbidities of COPD. Eur Respir Rev 2013; 22: 454–475.
30 Franzen D, Graf F, Wieser S, et al. Hospital care patterns in the management of acute exacerbated chronic
obstructive pulmonary disease – a retrospective analysis from Zurich, Switzerland. Eur Respir J 2014; 44: Suppl.
58, 795.
31 Gudmundsson G, Gislason T, Janson C, et al. Risk factors for rehospitalisation in COPD: role of health status,
anxiety and depression. Eur Respir J 2005; 26: 414–419.
32 Hasan MI, Haque R, Smyth C. Depression in chronic obstructive pulmonary disease – ignoring the obvious. Am J
Respir Crit Care Med 2011; 183: A2987.
33 Irwin DE, Atwood CA Jr, Hays RD, et al. Correlation of PROMIS scales and clinical measures among chronic
obstructive pulmonary disease patients with and without exacerbations. Qual Life Res 2015; 24: 999–1009.
34 Jennings JH, Thavarajah K, Mendez MP, et al. Predischarge bundle for patients with acute exacerbations of
chronic obstructive pulmonary disease to reduce readmissions and ED visits: a randomized, controlled trial. Chest
2015; 147: 1227–1234.
35 Kim MH, Lee K, Kim KU, et al. Risk factors associated with frequent hospital readmissions for exacerbation of
COPD. Tuberc Respir Dis 2010; 69: 243–249.
36 Koenig HG. Predictors of depression outcomes in medical inpatients with chronic pulmonary disease. Am J
Geriatr Psychiatry 2006; 14: 939–948.
37 Laçin A, Taskiran OO, Köktürk N, et al. Depression and related factors in pulmonary rehabilitation patients with
chronic obstructive pulmonary disease during exacerbation. Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi 2011; 57:
276.
38 Laurin C, Moullec G, Bacon SL, et al. The impact of psychological distress on exacerbation rates in COPD.
Ther Adv Respir Dis 2011; 5: 3–18.
39 Laurin C, Moullec G, Bacon SL, et al. Impact of anxiety and depression on chronic obstructive pulmonary disease
exacerbation risk. Am J Respir Crit Care Med 2012; 185: 918–923.
40 Ng TP, Niti M, Tan WC, et al. Clinical impact of comorbid depressive symptoms among patients with chronic
obstructive pulmonary disease. Ann Acad Med Singap 2014; 43: S58.
41 Ozyemisci-Taskiran O, Bozkurt SO, Kokturk N, et al. Is there any association between cognitive status and
functional capacity during exacerbation of chronic obstructive pulmonary disease? Chron Respir Dis 2015; 12:
247–255.
42 Panagioti M, Scott C, Blakemore A, et al. Overview of the prevalence, impact, and management of depression and
anxiety in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2014; 9: 1289–1306.
43 Papaioannou AI, Bartziokas K, Tsikrika S, et al. The impact of depressive symptoms on recovery and outcome of
hospitalised COPD exacerbations. Eur Respir J 2013; 41: 815–823.
44 Pooler A, Beech R. Examining the relationship between anxiety and depression and exacerbations of COPD which
result in hospital admission: a systematic review. Int J Chron Obstruct Pulmon Dis 2014; 9: 315–330.
45 Regvat J, Žmitek A, Vegnuti M, et al. Anxiety and depression during hospital treatment of exacerbation of chronic
obstructive pulmonary disease. J Int Med Res 2011; 39: 1028–1038.
46 Salte K, Titlestad I, Halling A. Depression is associated with poor prognosis in patients with chronic obstructive
pulmonary disease – a systematic review. Dan Med J 2015; 62: A5137.
47 Silver H, Blanchette CM, Roberts M, et al. Prevalence of comorbidities in patients hospitalized for COPD
exacerbations and impact on impatient mortality and hospital expenditures. Am J Respir Crit Care Med 2010; 181:
A5943.
48 Singh G, Zhang W, Kuo YF, et al. Association of psychological disorders with 30-day readmission rates in patients
with COPD. Chest 2016; 149: 905–915.
49 Small SP, Graydon JE. Perceived uncertainty, physical symptoms, and negative mood in hospitalized patients with
chronic obstructive pulmonary disease. Heart Lung 1992; 21: 568–574.
50 Struik FM, Kerstjens HA, Bladder G, et al. The Severe Respiratory Insufficiency Questionnaire scored best in the
assessment of health-related quality of life in chronic obstructive pulmonary disease. J Clin Epidemiol 2013; 66:
1166–1174.
51 Torres-Sánchez I, Valenza MC, Sáez-Roca G, et al. Results of a multimodal program during hospitalization in
obese COPD exacerbated patients. COPD 2016; 13: 19–25.
52 Valenza MC, Valenza-Peña G, Torres-Sánchez I, et al. Effectiveness of controlled breathing techniques on anxiety
and depression in hospitalized patients with COPD: a randomized clinical trial. Respir Care 2014; 59: 209–215.
53 Yıldırım A, Aşilar RH, Bakar N, et al. Effect of anxiety and depression on self-care agency and quality of life in
hospitalized patients with chronic obstructive pulmonary disease: a questionnaire survey. Int J Nurs Pract 2013; 19:
14–22.
54 Smith HR. Depression in cancer patients: pathogenesis, implications and treatment (review). Oncol Lett 2015; 9:
1509–1514.
55 European AIDS Clinical Society. Guidelines Version 8.1. www.eacsociety.org/files/guidelines_8.1-english.pdf Date
last accessed: November 3, 2016. Date last updated: October 2016.
56 Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361–370.
57 Bjelland I, Dahl AA, Haug TT, et al. The validity of the hospital anxiety and depression scale. An updated
literature review. J Psychosom Res 2002; 52: 69–77.
58 Harzing A-W. Response styles in cross-national survey research: a 26-country study. Int J Cross Cult Manag 2006;
6: 243–266.
59 Siu AL. Screening for depression in children and adolescents: US Preventive Services Task Force recommendation
statement. Pediatrics 2016; 137: e20154467.
https://doi.org/10.1183/16000617.0026-2017 12
COPD | L. LECHELER ET AL.
